{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T01:43:50Z","timestamp":1779327830232,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Charcot\u2013Marie\u2013Tooth Type 1\u00a0A (CMT1A) is a hereditary neuropathy caused by a duplication of the peripheral myelin protein 22 (PMP22) gene. Emerging evidence suggests that lipid metabolism plays a central role in CMT1A pathology. This study investigated metabolic profiles in sciatic nerve tissue and plasma of PMP22 transgenic (TG) and wild-type (WT) rats at 2, 4, and 6 months of age. Utilizing targeted metabolomics, more than 600 metabolites covering central metabolic pathways and major lipid classes were analyzed, revealing distinct age-dependent changes in metabolic pathways. Alterations that emerged early and became increasingly pronounced with age were observed in sphingolipids and glycerophospholipids, while changes in other metabolic pathways, such as amino acids, storage lipids, bile acids, and nucleotide metabolism, were age-specific. Notably, in contrast to these age-dependent adaptive changes, three lipid signatures were identified that remained stable from the earliest age examined. These include: (1) an elevated ratio of hydroxylated to non-hydroxylated sphingolipids, (2) a reduced ratio of monounsaturated-containing to saturated fatty acid containing phosphatidylcholines, and (3) a decreased ratio of hexosylceramides to ceramides. Imaging mass spectrometry analyses confirmed disruptions in sphingolipid metabolism. These findings suggest a key regulatory role of PMP22 in lipid metabolism, as demonstrated by the early stabilization of specific lipid signatures compared to other metabolic changes that occurred in an age-dependent and adaptive manner. These observations provide valuable insights into the pathogenic mechanisms underlying CMT1A.<\/jats:p>","DOI":"10.1038\/s41598-025-31633-7","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:43:56Z","timestamp":1767897836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic signatures in sciatic nerve of PMP22 transgenic rats provide insights into the pathogenesis of charcot-marie-tooth disease type 1\u00a0A"],"prefix":"10.1038","volume":"16","author":[{"given":"Alban","family":"Muller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3831-5911","authenticated-orcid":false,"given":"Kerri","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Christen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Kreider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaila","family":"Hoque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bidinosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-2773","authenticated-orcid":false,"given":"Shinji","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-8279","authenticated-orcid":false,"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"31633_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ncl.2013.01.009","volume":"31","author":"MA Saporta","year":"2013","unstructured":"Saporta, M. A. & Shy, M. E. Inherited peripheral neuropathies. Neurol. Clin. 31, 597\u2013619. https:\/\/doi.org\/10.1016\/j.ncl.2013.01.009 (2013).","journal-title":"Neurol. Clin."},{"key":"31633_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/mgg3.106","volume":"2","author":"C DiVincenzo","year":"2014","unstructured":"DiVincenzo, C. et al. The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. Mol. Genet. Genomic Med. 2, 522\u2013529. https:\/\/doi.org\/10.1002\/mgg3.106 (2014).","journal-title":"Mol. Genet. Genomic Med."},{"key":"31633_CR3","doi-asserted-by":"publisher","unstructured":"Morena, J., Gupta, A. & Hoyle, J. C. Charcot-Marie-Tooth: from molecules to therapy. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20143419 (2019).","DOI":"10.3390\/ijms20143419"},{"key":"31633_CR4","doi-asserted-by":"publisher","first-page":"930435","DOI":"10.3389\/fneur.2022.930435","volume":"13","author":"K Eichinger","year":"2022","unstructured":"Eichinger, K. et al. Accelerate clinical trials in Charcot-Marie-Tooth disease (ACT-CMT): A protocol to address clinical trial readiness in CMT1A. Front. Neurol. 13, 930435. https:\/\/doi.org\/10.3389\/fneur.2022.930435 (2022).","journal-title":"Front. Neurol."},{"key":"31633_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jns.12539","volume":"28","author":"A Bolino","year":"2023","unstructured":"Bolino, A. & D\u2019Antonio, M. Recent advances in the treatment of Charcot-Marie-Tooth neuropathies. J. Peripher Nerv. Syst. 28, 134\u2013149. https:\/\/doi.org\/10.1111\/jns.12539 (2023).","journal-title":"J. Peripher Nerv. Syst."},{"key":"31633_CR6","doi-asserted-by":"publisher","unstructured":"Okamoto, Y. & Takashima, H. The current state of Charcot-Marie-Tooth disease treatment. Genes (Basel). 14. https:\/\/doi.org\/10.3390\/genes14071391 (2023).","DOI":"10.3390\/genes14071391"},{"key":"31633_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/acn3.432","volume":"4","author":"J Li","year":"2017","unstructured":"Li, J. Caveats in the established Understanding of CMT1A. Ann. Clin. Transl Neurol. 4, 601\u2013607. https:\/\/doi.org\/10.1002\/acn3.432 (2017).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"31633_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ng0692-159","volume":"1","author":"PI Patel","year":"1992","unstructured":"Patel, P. I. et al. The gene for the peripheral Myelin Protein-Pmp-22 is a candidate for Charcot-Marie-Tooth disease Type-1a. Nat. Genet. 1, 159\u2013165. https:\/\/doi.org\/10.1038\/ng0692-159 (1992).","journal-title":"Nat. Genet."},{"key":"31633_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng0692-171","volume":"1","author":"V Timmerman","year":"1992","unstructured":"Timmerman, V. et al. The peripheral Myelin protein gene Pmp-22 is contained within the Charcot-Marie-Tooth disease Type-1a duplication. Nat. Genet. 1, 171\u2013175. https:\/\/doi.org\/10.1038\/ng0692-171 (1992).","journal-title":"Nat. Genet."},{"key":"31633_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng0692-166","volume":"1","author":"LJ Valentijn","year":"1992","unstructured":"Valentijn, L. J. et al. The peripheral Myelin gene Pmp-22\/Gas-3 is duplicated in Charcot-Marie-Tooth disease Type-1a. Nat. Genet. 1, 166\u2013170. https:\/\/doi.org\/10.1038\/ng0692-166 (1992).","journal-title":"Nat. Genet."},{"key":"31633_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jnnp-2012-302451","volume":"83","author":"SM Murphy","year":"2012","unstructured":"Murphy, S. M. et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J. Neurol. Neurosurg. Psychiatry. 83, 706\u2013710. https:\/\/doi.org\/10.1136\/jnnp-2012-302451 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"31633_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1083\/jcb.117.1.225","volume":"117","author":"GJ Snipes","year":"1992","unstructured":"Snipes, G. J., Welcher, S. U. & Shooter, A. A. Characterization of a novel peripheral nervous system Myelin protein (PMP22\/SR13). J Cell. Biol. Apr. 117 (1), 225\u2013238. https:\/\/doi.org\/10.1083\/jcb.117.1.225 (1992).","journal-title":"J Cell. Biol. Apr"},{"key":"31633_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/ng1195-274","volume":"11","author":"K Adlkofer","year":"1995","unstructured":"Adlkofer, K. et al. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat. Genet. 11, 274\u2013280. https:\/\/doi.org\/10.1038\/ng1195-274 (1995).","journal-title":"Nat. Genet."},{"key":"31633_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/s0079-6603(00)64003-5","volume":"64","author":"AM Jetten","year":"2000","unstructured":"Jetten, A. M. & Suter, U. The peripheral Myelin protein 22 and epithelial membrane protein family. Prog Nucleic Acid Res. Mol. Biol. 64, 97\u2013129. https:\/\/doi.org\/10.1016\/s0079-6603(00)64003-5 (2000).","journal-title":"Prog Nucleic Acid Res. Mol. Biol."},{"key":"31633_CR15","doi-asserted-by":"crossref","unstructured":"Mittendorf, K. F. et al. Peripheral myelin protein 22 alters membrane architecture. Sci Adv 3 (2017). https:\/\/doi.org\/ARTN e170022010.1126\/sciadv.1700220.","DOI":"10.1126\/sciadv.1700220"},{"key":"31633_CR16","doi-asserted-by":"publisher","unstructured":"Prior, R. et al. Defective Schwann cell lipid metabolism alters plasma membrane dynamics in Charcot-Marie-Tooth disease 1A. bioRxiv (2023). https:\/\/doi.org\/10.1101\/2023.04.02.535224","DOI":"10.1101\/2023.04.02.535224"},{"key":"31633_CR17","doi-asserted-by":"publisher","unstructured":"Poitelon, Y., Kopec, A. M. & Belin, S. Myelin fat facts: an overview of lipids and fatty acid metabolism. Cells 9 https:\/\/doi.org\/10.3390\/cells9040812 (2020).","DOI":"10.3390\/cells9040812"},{"key":"31633_CR18","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.4103\/1673-5374.367834","volume":"18","author":"N Hertzog","year":"2023","unstructured":"Hertzog, N. & Jacob, C. Mechanisms and treatment strategies of demyelinating and dysmyelinating Charcot-Marie-Tooth disease. Neural Regeneration Res. 18, 1931\u20131939. https:\/\/doi.org\/10.4103\/1673-5374.367834 (2023).","journal-title":"Neural Regeneration Res."},{"key":"31633_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.bbalip.2014.12.016","volume":"1851","author":"S Schmitt","year":"2015","unstructured":"Schmitt, S., Castelvetri, L. C. & Simons, M. Metabolism and functions of lipids in Myelin. Biochim. Biophys. Acta. 1851, 999\u20131005. https:\/\/doi.org\/10.1016\/j.bbalip.2014.12.016 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"31633_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1242\/bio.019273","volume":"5","author":"P Bais","year":"2016","unstructured":"Bais, P. et al. Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions. Biol. Open. 5, 908\u2013920. https:\/\/doi.org\/10.1242\/bio.019273 (2016).","journal-title":"Biol. Open."},{"key":"31633_CR21","doi-asserted-by":"publisher","first-page":"e0178376","DOI":"10.1371\/journal.pone.0178376","volume":"12","author":"B Soldevilla","year":"2017","unstructured":"Soldevilla, B. et al. Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients. PLoS One. 12, e0178376. https:\/\/doi.org\/10.1371\/journal.pone.0178376 (2017).","journal-title":"PLoS One"},{"key":"31633_CR22","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1038\/s41467-018-05420-0","volume":"9","author":"R Fledrich","year":"2018","unstructured":"Fledrich, R. et al. Targeting Myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nat. Commun. 9, 3025. https:\/\/doi.org\/10.1038\/s41467-018-05420-0 (2018).","journal-title":"Nat. Commun."},{"key":"31633_CR23","doi-asserted-by":"publisher","first-page":"1543547","DOI":"10.3389\/fneur.2025.1543547","volume":"16","author":"S Setlere","year":"2025","unstructured":"Setlere, S. et al. Metabolomics insights into Charcot-Marie-Tooth disease: toward biomarker discovery. Front. Neurol. 16, 1543547. https:\/\/doi.org\/10.3389\/fneur.2025.1543547 (2025).","journal-title":"Front. Neurol."},{"key":"31633_CR24","doi-asserted-by":"publisher","unstructured":"Bustos, A. et al. Metabolic and functional improvements in a patient with Charcot-Marie-Tooth disease type 2 after EGCG administration: A case report. Med. (Kaunas). 57,\u00a0https:\/\/doi.org\/10.3390\/medicina57020104 (2021).","DOI":"10.3390\/medicina57020104"},{"key":"31633_CR25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/s0896-6273(00)80128-2","volume":"16","author":"M Sereda","year":"1996","unstructured":"Sereda, M. et al. A Transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16, 1049\u20131060. https:\/\/doi.org\/10.1016\/s0896-6273(00)80128-2 (1996).","journal-title":"Neuron"},{"key":"31633_CR26","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1007\/s13311-021-01145-z","volume":"18","author":"V Fridman","year":"2021","unstructured":"Fridman, V. & Saporta, M. A. Mechanisms and treatments in demyelinating CMT. Neurotherapeutics 18, 2236\u20132268. https:\/\/doi.org\/10.1007\/s13311-021-01145-z (2021). https:\/\/doi.org\/","journal-title":"Neurotherapeutics"},{"key":"31633_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3389\/fneur.2020.00903","volume":"11","author":"D Visigalli","year":"2020","unstructured":"Visigalli, D. et al. Exploiting Sphingo- and glycerophospholipid impairment to select effective drugs and biomarkers for CMT1A. Front. Neurol. 11, 903. https:\/\/doi.org\/10.3389\/fneur.2020.00903 (2020).","journal-title":"Front. Neurol."},{"key":"31633_CR28","doi-asserted-by":"publisher","unstructured":"O\u2019Brien, J. Stability of Myeline membrane. Science 147, 1099\u20131107. https:\/\/doi.org\/10.1126\/science.147.3662.1099 (1965).","DOI":"10.1126\/science.147.3662.1099"},{"key":"31633_CR29","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1194\/jlr.RA120000671","volume":"61","author":"M Kawana","year":"2020","unstructured":"Kawana, M., Miyamoto, M., Ohno, Y. & Kihara, A. Comparative profiling and comprehensive quantification of stratum corneum ceramides in humans and mice by LC\/MS\/MS. J. Lipid Res. 61, 884\u2013895. https:\/\/doi.org\/10.1194\/jlr.RA120000671 (2020).","journal-title":"J. Lipid Res."},{"key":"31633_CR30","doi-asserted-by":"publisher","unstructured":"Eckhardt, M. & Fatty Acid 2-Hydroxylase and 2-Hydroxylated sphingolipids: metabolism and function in health and diseases. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms24054908 (2023).","DOI":"10.3390\/ijms24054908"},{"key":"31633_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.plipres.2018.05.001","volume":"71","author":"JT Marques","year":"2018","unstructured":"Marques, J. T., Marinho, H. S. & de Almeida, R. F. M. Sphingolipid hydroxylation in mammals, yeast and plants - An integrated view. Prog Lipid Res. 71, 18\u201342. https:\/\/doi.org\/10.1016\/j.plipres.2018.05.001 (2018).","journal-title":"Prog Lipid Res."},{"key":"31633_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbalip.2009.12.004","volume":"1801","author":"H Hama","year":"2010","unstructured":"Hama, H. Fatty acid 2-Hydroxylation in mammalian sphingolipid biology. Biochim. Biophys. Acta. 1801, 405\u2013414. https:\/\/doi.org\/10.1016\/j.bbalip.2009.12.004 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"31633_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.bbamem.2010.12.006","volume":"1808","author":"O Ekholm","year":"2011","unstructured":"Ekholm, O., Jaikishan, S., Lonnfors, M., Nyholm, T. K. & Slotte, J. P. Membrane bilayer properties of sphingomyelins with amide-linked 2- or 3-hydroxylated fatty acids. Biochim. Biophys. Acta. 1808, 727\u2013732. https:\/\/doi.org\/10.1016\/j.bbamem.2010.12.006 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"31633_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1476-511X-10-84","volume":"10","author":"P Dan","year":"2011","unstructured":"Dan, P., Edvardson, S., Bielawski, J., Hama, H. & Saada, A. 2-Hydroxylated sphingomyelin profiles in cells from patients with mutated fatty acid 2-hydroxylase. Lipids Health Dis. 10, 84. https:\/\/doi.org\/10.1186\/1476-511X-10-84 (2011).","journal-title":"Lipids Health Dis."},{"key":"31633_CR35","doi-asserted-by":"publisher","first-page":"48562","DOI":"10.1074\/jbc.M406649200","volume":"279","author":"NL Alderson","year":"2004","unstructured":"Alderson, N. L. et al. The human FA2H gene encodes a fatty acid 2-hydroxylase. J. Biol. Chem. 279, 48562\u201348568. https:\/\/doi.org\/10.1074\/jbc.M406649200 (2004).","journal-title":"J. Biol. Chem."},{"key":"31633_CR36","doi-asserted-by":"publisher","unstructured":"German, A. et al. Novel homozygous FA2H variant causing the full spectrum of fatty acid Hydroxylase-Associated neurodegeneration (SPG35). Genes (Basel). 15. https:\/\/doi.org\/10.3390\/genes15010014 (2023).","DOI":"10.3390\/genes15010014"},{"key":"31633_CR37","doi-asserted-by":"crossref","unstructured":"Dan, P., Edvardson, S., Bielawski, J., Hama, H. & Saada A. 2-hydroxylated sphingomyelin profiles in cells from patients with mutated fatty acid 2-hydroxylase. Lipids Health Dis. 10, 84. https:\/\/doi.org\/10.1186\/1476-511X-10-84 (2011).","DOI":"10.1186\/1476-511X-10-84"},{"key":"31633_CR38","doi-asserted-by":"publisher","unstructured":"Capodivento, G. et al. Monitoring Myelin lipid composition and the structure of myelinated fibers reveals a maturation delay in CMT1A. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms252011244 (2024).","DOI":"10.3390\/ijms252011244"},{"key":"31633_CR39","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/glycob\/cwab046","volume":"31","author":"S Reza","year":"2021","unstructured":"Reza, S., Ugorski, M. & Suchanski, J. Glucosylceramide and galactosylceramide, small glycosphingolipids with significant impact on health and disease. Glycobiology 31, 1416\u20131434. https:\/\/doi.org\/10.1093\/glycob\/cwab046 (2021).","journal-title":"Glycobiology"},{"key":"31633_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/glia.20930","volume":"58","author":"L Saadat","year":"2010","unstructured":"Saadat, L. et al. Absence of oligodendroglial glucosylceramide synthesis does not result in CNS Myelin abnormalities or alter the dysmyelinating phenotype of CGT-Deficient mice. Glia 58, 391\u2013398. https:\/\/doi.org\/10.1002\/glia.20930 (2010).","journal-title":"Glia"},{"key":"31633_CR41","doi-asserted-by":"publisher","first-page":"135455","DOI":"10.1016\/j.neulet.2020.135455","volume":"740","author":"T Hornemann","year":"2021","unstructured":"Hornemann, T. Mini review: lipids in peripheral nerve disorders. Neurosci. Lett. 740, 135455. https:\/\/doi.org\/10.1016\/j.neulet.2020.135455 (2021).","journal-title":"Neurosci. Lett."},{"key":"31633_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.biochi.2022.08.010","volume":"203","author":"V Naffaa","year":"2022","unstructured":"Naffaa, V. et al. Shift in phospholipid and fatty acid contents accompanies brain myelination. Biochimie 203, 20\u201331. https:\/\/doi.org\/10.1016\/j.biochi.2022.08.010 (2022).","journal-title":"Biochimie"},{"key":"31633_CR43","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1172\/JCI131800","volume":"130","author":"X Zhou","year":"2020","unstructured":"Zhou, X. et al. Mature Myelin maintenance requires Qki to coactivate PPARbeta-RXRalpha-mediated lipid metabolism. J. Clin. Invest. 130, 2220\u20132236. https:\/\/doi.org\/10.1172\/JCI131800 (2020).","journal-title":"J. Clin. Invest."},{"issue":"19980215","key":"31633_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/(SICI)1097-4547","volume":"51","author":"RJ Hardy","year":"1998","unstructured":"Hardy, R. J. Molecular defects in the dysmyelinating mutant quaking. J. Neurosci. Res. 51 (19980215), 417\u2013422. https:\/\/doi.org\/10.1002\/(SICI)1097-4547 (1998). ::AID-JNR1>3.0.CO;2-F","journal-title":"J. Neurosci. Res."},{"key":"31633_CR45","doi-asserted-by":"publisher","first-page":"11278","DOI":"10.1523\/JNEUROSCI.2677-06.2006","volume":"26","author":"L Zhao","year":"2006","unstructured":"Zhao, L., Tian, D., Xia, M., Macklin, W. B. & Feng, Y. Rescuing QkV dysmyelination by a single isoform of the selective RNA-binding protein QKI. J. Neurosci. 26, 11278\u201311286. https:\/\/doi.org\/10.1523\/JNEUROSCI.2677-06.2006 (2006).","journal-title":"J. Neurosci."},{"key":"31633_CR46","doi-asserted-by":"crossref","unstructured":"Bogie, J. F. J. et al. Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain. J Exp Med 217 (2020). https:\/\/doi.org\/ARTN e2019166010.1084\/jem.20191660.","DOI":"10.1084\/jem.20191660"},{"key":"31633_CR47","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1038\/srep06992","volume":"4","author":"T Hara","year":"2014","unstructured":"Hara, T. et al. Rer1 and calnexin regulate Endoplasmic reticulum retention of a peripheral Myelin protein 22 mutant that causes type 1A Charcot-Marie-Tooth disease. Sci. Rep. 4, 6992. https:\/\/doi.org\/10.1038\/srep06992 (2014).","journal-title":"Sci. Rep."},{"key":"31633_CR48","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1007\/s12035-022-02838-y","volume":"59","author":"Y Bai","year":"2022","unstructured":"Bai, Y. et al. Treatment with IFB-088 improves neuropathy in CMT1A and CMT1B mice. Mol. Neurobiol. 59, 4159\u20134178. https:\/\/doi.org\/10.1007\/s12035-022-02838-y (2022).","journal-title":"Mol. Neurobiol."},{"key":"31633_CR49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrn2797","volume":"11","author":"KA Nave","year":"2010","unstructured":"Nave, K. A. Myelination and the trophic support of long axons. Nat. Rev. Neurosci. 11, 275\u2013283. https:\/\/doi.org\/10.1038\/nrn2797 (2010).","journal-title":"Nat. Rev. Neurosci."},{"key":"31633_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41536-023-00345-9","volume":"9","author":"J Hu","year":"2024","unstructured":"Hu, J. et al. Myeloid cell-associated aromatic amino acid metabolism facilitates CNS Myelin regeneration. NPJ Regen Med. 9, 1. https:\/\/doi.org\/10.1038\/s41536-023-00345-9 (2024).","journal-title":"NPJ Regen Med."},{"key":"31633_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10545-017-0063-1","volume":"40","author":"TJ de Koning","year":"2017","unstructured":"de Koning, T. J. Amino acid synthesis deficiencies. J. Inherit. Metab. Dis. 40, 609\u2013620. https:\/\/doi.org\/10.1007\/s10545-017-0063-1 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"31633_CR52","doi-asserted-by":"publisher","first-page":"100345","DOI":"10.1016\/j.xcrm.2021.100345","volume":"2","author":"AJ Clark","year":"2021","unstructured":"Clark, A. J. et al. An iPSC model of hereditary sensory neuropathy-1 reveals L-serine-responsive deficits in neuronal ganglioside composition and axoglial interactions. Cell. Rep. Med. 2, 100345. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100345 (2021).","journal-title":"Cell. Rep. Med."},{"key":"31633_CR53","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1194\/jlr.RA120000627","volume":"61","author":"DL Davis","year":"2020","unstructured":"Davis, D. L. et al. Dynamics of sphingolipids and the Serine palmitoyltransferase complex in rat oligodendrocytes during myelination. J. Lipid Res. 61, 505\u2013522. https:\/\/doi.org\/10.1194\/jlr.RA120000627 (2020).","journal-title":"J. Lipid Res."},{"key":"31633_CR54","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.3390\/molecules29245934","volume":"29","author":"NK Anh","year":"2024","unstructured":"Anh, N. K., Thu, N. Q., Tien, N. T. N., Long, N. P. & Nguyen, H. T. Advancements in mass Spectrometry-Based targeted metabolomics and lipidomics: implications for clinical research. Molecules 29, 5934 (2024).","journal-title":"Molecules"},{"key":"31633_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11306-024-02108-z","volume":"20","author":"R Xu","year":"2024","unstructured":"Xu, R., Zhang, S., Li, J. & Zhu, J. Plasma and serum metabolic analysis of healthy adults shows characteristic profiles by subjects\u2019 sex and age. Metabolomics 20, 43. https:\/\/doi.org\/10.1007\/s11306-024-02108-z (2024).","journal-title":"Metabolomics"},{"key":"31633_CR56","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1021\/acs.jproteome.1c00935","volume":"21","author":"A Vignoli","year":"2022","unstructured":"Vignoli, A. et al. Serum or plasma (and which plasma), that is the question. J. Proteome Res. 21, 1061\u20131072. https:\/\/doi.org\/10.1021\/acs.jproteome.1c00935 (2022).","journal-title":"J. Proteome Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31633-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:22:26Z","timestamp":1768479746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31633-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31633"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31633-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2036"}}